Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: LIVER FAILURE, ACUTE Clear all
Completed Phase 3 Interventional Results available

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

NCT01471028
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
ELAD treatment, Standard of care (Control)
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

NCT02921828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Results available

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

NCT00248625
View directory record Official record
Conditions
Acute Liver Failure, Hepatic Encephalopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Jul 21, 2026, 11:16 AM EDT
Suspended No phase listed Observational

Longitudinal Study of Mitochondrial Hepatopathies

NCT01148550
View directory record Official record
Conditions
Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Hypothermia to Prevent High Intracranial Pressure in Patients With Acute Liver Failure

NCT00670124
View directory record Official record
Conditions
Acute Liver Failure, Intracranial Hypertension
Interventions
Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero
Device
Lead sponsor
Rigshospitalet, Denmark
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure

NCT00030225
View directory record Official record
Conditions
Fulminant Hepatic Failure
Interventions
ELAD, Standard of care (Control)
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Jul 21, 2026, 11:16 AM EDT
Terminated Phase 2Phase 3 Interventional

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

NCT06000748
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome, Acute Tubule Necrosis, Prerenal Failure
Interventions
MAP-Target Algorithm
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 21, 2026, 11:16 AM EDT
Terminated Phase 3 Interventional Results available

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

NCT02612428
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
ELAD System, Standard of Care (Control)
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Coronado, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 21, 2026, 11:16 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)

NCT00832728
View directory record Official record
Conditions
Fulminant Hepatic Failure
Interventions
Standard of Care, ELAD®
Other · Device
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
10 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 3 Interventional

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

NCT00004467
View directory record Official record
Conditions
Acute Liver Failure
Interventions
N-acetylcysteine (NAC), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational

Collection of Liver Tissue for Virologic Studies

NCT00005936
View directory record Official record
Conditions
Virus Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 1 Interventional

miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

NCT06285253
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
Interventions
miroliverELAP treatment
Combination Product
Lead sponsor
Miromatrix Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Cardiox Liver Function Test Pivotal Trial

NCT02552901
View directory record Official record
Conditions
Hepatic Failure, Liver Failure
Interventions
0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
Drug
Lead sponsor
Cardiox Corporation
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Jul 21, 2026, 11:16 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Jul 21, 2026, 11:16 AM EDT
Terminated Phase 3 Interventional Results available

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

NCT03702920
View directory record Official record
Conditions
Acute-On-Chronic Liver Failure
Interventions
SMT + PE-A 5%, Standard Medical Treatment
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

NCT02786836
View directory record Official record
Conditions
Acute Liver Failure
Interventions
13C-Methacetin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jul 21, 2026, 11:16 AM EDT
Terminated No phase listed Observational

Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients

NCT06263114
View directory record Official record
Conditions
Liver Transplant; Complications, Liver Failure, Acute
Interventions
TruGraf® Liver gene expression panel (GEP)
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 1Phase 2 Interventional

Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency

NCT00771446
View directory record Official record
Conditions
Acute Hepatitis, Chronic Hepatitis
Interventions
ELAD plus standard of care treatment, Standard of care treatment
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
19 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • San Francisco, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Jul 21, 2026, 11:16 AM EDT
Withdrawn Phase 1 Interventional

Hepatocyte Transplantation for Acute Decompensated Liver Failure

NCT01345565
View directory record Official record
Conditions
Liver Failure Acute
Interventions
human hepatocytes
Drug
Lead sponsor
Ira Fox
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational

A Multi-Center Trial to Study Acute Liver Failure in Adults

NCT00518440
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Acute Liver Injury
Interventions
Not listed
Lead sponsor
William Lee
Other
Eligibility
18 Years and older
Enrollment
3,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Jul 21, 2026, 11:16 AM EDT
Terminated Phase 2 Interventional

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
View directory record Official record
Conditions
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions
VS-01 on top of SOC (Active Treatment Group), SOC
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Jul 21, 2026, 11:16 AM EDT